A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
Items 101–200 of 572
Pharmacotherapy of alcoholism – an update on approved and off-label medications
Soyka, M., & Müller, C. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349098 · Cited by 86
Roozen, H. G., de Waart, R., van der Windt, D., van den Brink, W., de Jong, C. A. J., & Kerkhof, A. J. F. M. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.11.001 · Cited by 97
Pharmacotherapy for Alcohol Use Disorder: Current and Emerging Therapies
Swift, R. M., & Aston, E. R. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000079 · Cited by 93
Common single nucleotide variants underlying drug addiction: more than a decade of research
Bühler, K., Giné, E., Echeverry‐Alzate, V., Calleja‐Conde, J., de Fonseca, F. R., & López‐Moreno, J. A. (2015) · Addiction Biology · doi:10.1111/adb.12204 · Cited by 88
“Several studies have shown that G carriers had a significantly better clinical outcome with the opioid antagonist than A carriers (Oslin et al. 2003; Ray & Hutchison 2004, 2007), making the A118G an important marker to take into account in the pharmacological treatment of alcohol dependence.”
BackgroundA pilot trial of low-dose naltrexone in primary progressive multiple sclerosis
Gironi, M., Boneschi, F. M., Sacerdote, P., Solaro, C. M., Zaffaroni, M., Cavarretta, R., Moiola, L., Bucello, S., Radaelli, M., Pilato, V., et al. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508095828 · Cited by 98
“, protein concentrations of BE and mRNA levels of its receptor, the μ-opioid receptor (MOR)] was also evaluated together with the allelic variants of the human MOR gene OPRM1 [12].”
MethodMann, K., Kiefer, F., Smolka, M., Gann, H., Wellek, S., Heinz, A., & and the PREDICT Study research team (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00884.x · Cited by 93
Verheul, R., Lehert, P., Geerlings, P. J., Koeter, M. W. J., & van den Brink, W. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1991-7 · Cited by 94
“To the extent that this explanation is viable, a matching trial using neurobiological predictors (e.g. glutamate-induced excitotoxicity, allelic variations [Oslin et al. 2003]) and standardized measures of psychological and psychophysiological measures should be considered.”
BackgroundMann, K., Vollstädt‐Klein, S., Reinhard, I., Leménager, T., Fauth‐Bühler, M., Hermann, D., Hoffmann, S., Zimmermann, U. S., Kiefer, F., Heinz, A., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12546 · Cited by 90
The opioid system in alcohol and drug dependence: Family‐based association study
Xuei, X., Wetherill, L. F., Bierut, L. J., Dick, D. M., Nürnberger, J. I., Foroud, T., & Edenberg, H. J. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30531 · Cited by 96
Kim, S., Kim, C.-M., Choi, S., Jae, Y.-M., Lee, H.-G., Son, B., Kim, J., Choi, Y.-S., Kim, H.-O., Kim, S., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1330-5 · Cited by 98
“Two genetic polymorphisms, A118G (Asn40Asp) and C17T (Ala6Val), in exon 1 of OPRM1 are drawing the most attention (Oslin et al. 2003).”
BackgroundResultSelf-citationBreaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction
Ho, M. K., Goldman, D., Heinz, A., Kaprio, J., Kreek, M. J., Li, M. D., Munafò, M. R., & Tyndale, R. F. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.175 · Cited by 87
RUBIO, G., PONCE, G., RODRIGUEZ-JIMÉNEZ, R., JIMÉNEZ-ARRIERO, M. A., HOENICKA, J., & PALOMO, T. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh151 · Cited by 89
“A functional polymorphism of the mu-opioid receptor gene has recently been associated with NTX response in alcoholic patients (Oslin et al., 2003).”
Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone
Bach, P., Weil, G., Pompili, E., Hoffmann, S., Hermann, D., Vollstädt‐Klein, S., Mann, K., Perez‐Ramirez, U., Moratal, D., Canals, S., et al. (2020) · Addiction Biology · doi:10.1111/adb.12717 · Cited by 85
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system
Patriquin, M. A., Bauer, I. E., Soares, J. C., Graham, D. P., & Nielsen, D. A. (2015) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000095 · Cited by 98
“It has been shown that the A118G rs1788821 variant alters response to naltrexone treatment for alcoholism (Oslin et al., 2003; Anton et al., 2008).”
Endogenous Opioid Blockade and Impulsive Responding in Alcoholics and Healthy Controls
Mitchell, J., Tavares, V. C., Fields, H. L., D’Esposito, M., & Boettiger, C. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301226 · Cited by 96
Schacht, J. P., Anton, R. F., Voronin, K. E., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.195 · Cited by 91
Enoch, M., Johnson, K. E., George, D. T., Schumann, G., Moss, H. B., Kranzler, H. R., & Goldman, D. A. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00988.x · Cited by 87
Self-citationA cognitive model for the intergenerational transference of alcohol use behavior
Campbell, J. M., & Oei, T. P. S. (2009) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.09.013 · Cited by 97
“…et al., 2006), Chromosome 5 (Ehlers & Wilhelmsen, 2005), Chromosome 15 (Dick et al., 2004); the µ-opioid receptor gene (Nishizawa et al., 2006; Oslin et al., 2003), GABAreceptor genes (Edenberg et al., 2004; Fehret al., 2006; Sander et al., 1999), the serotonin transporter gene (LeMarquand…”
BackgroundOPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach
Oroszi, G., Anton, R. F., O’Malley, S., Swift, R., Pettinati, H., Couper, D., Yuan, Q., & Goldman, D. (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00846.x · Cited by 84
“As mentioned above Asp40 has been shown to be predictive of response to naltrexone treatment in alcoholics by ourselves and at least one other group, (Anton et al., 2008; Oslin et al., 2003) and evidence has been provided for the in vitro and in vivo functionality of this missense variant.”
BackgroundSelf-citationSoyka, M., Kranzler, H. R., Hesselbrock, V., Kasper, S., Mutschler, J., Möller, H.-J., & The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1246752 · Cited by 85
“In some naltrexone studies, for example, carriers of a variant (118G or Asp40) allele in OPRM1, which encodes the l-opioid receptor, had better treatment responses to naltrexone than did 118A (or Asn40) allele homozygotes (Oslin et al. 2003; Anton 2008).”
BackgroundSelf-citationPharmacogenomics of Alcohol Response and Addiction
Enoch, M. (2003) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200303040-00001 · Cited by 93
Bazov, I., Kononenko, O., Watanabe, H., Kuntić, V., Sarkisyan, D., Taqi, M. M., Hussain, M. Z., Nyberg, F., Yakovleva, T., & Bakalkin, G. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00366.x · Cited by 81
“…k- (OPRK1) opioid receptor genes, and the prodynorphin (PDYN) gene that gives rise to dynorphins, the endogenous k-opioid receptor (KOR) ligands, are associated with alcoholism (Oslin et al. 2003; Bart et al. 2005; Xuei et al. 2006; Xuei et al. 2007; Edenberg et al. 2008; Ramchandani et al. 2010).”
BackgroundPharmacotherapy and Pharmacogenetics of Nicotine Dependence
Berrettini, W. H., & Lerman, C. E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1441 · Cited by 86
Self-citationTreating Tobacco Dependence: State of the Science and New Directions
Lerman, C., Patterson, F., & Berrettini, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.058 · Cited by 88
Self-citationPharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
A systems medicine research approach for studying alcohol addiction
Spanagel, R., Durstewitz, D., Hansson, A., Heinz, A., Kiefer, F., Köhr, G., Matthäus, F., Nöthen, M. M., Noori, H. R., Obermayer, K., et al. (2013) · Addiction Biology · doi:10.1111/adb.12109 · Cited by 81
“…it has recently been demonstrated that a functional single nucleotide polymorphism (Asn40Asp) in the μ-opioid receptor gene predicts naltrexone efficacy as measured by relapse behavior (Oslin et al. 2003; Anton et al. 2008; Kranzler et al. 2013; for a first meta-analysis see Chamorro et al. 2012).”
BackgroundRay, L. A. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01333.x · Cited by 81
“…of this polymorphism to alcoholism etiology and treatment evolves, particularly the pharmacogenetics of naltrexone (Oroszi et al., 2008; Oslin et al., 2003; Ray and Hutchison, 2007), it appears as though mechanisms of reward, not punishment or stress, may be most salient to the risk…”
BackgroundGarbutt, J. C., Greenblatt, A. M., West, S. L., Morgan, L. C., Kampov‐Polevoy, A., Jordan, H. S., & Bobashev, G. V. (2014) · Addiction · doi:10.1111/add.12557 · Cited by 81
“[27] reported that those with the Asn40Asp allele who received naltrexone had lower relapse rates than those without the allele (no effect was found in the placebo group).”
BackgroundOoteman, W., Naassila, M., Koeter, M. W. J., Verheul, R., Schippers, G. M., Houchi, H., Daoust, M., & Van Den Brink, W. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00159.x · Cited by 80
Boettiger, C. A., Kelley, E. A., Mitchell, J. M., D'Esposito, M., & Fields, H. L. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.02.008 · Cited by 77
“Moreover, clinical trials have yielded some data demonstrating that that the ASP40 variant predicts therapeutic response to NTX (Anton et al., 2008; Oslin et al., 2003); although, other studies have failed to replicate this finding (Gelernter et al., 2007).”
Microarray Studies of Psychostimulant-Induced Changes in Gene Expression
Yuferov, V., Nielsen, D., Butelman, E., & Kreek, M. J. (2005) · Addiction Biology · doi:10.1080/13556210412331308976 · Cited by 81
“Of further relevance, the A118G polymorphism is associated with a more favourable response to naltrexone therapy in alcoholism (Oslin et al., 2003).”
BackgroundNew Pharmacological Treatment Strategies for Relapse Prevention
Spanagel, R., & Vengeliene, V. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_205 · Cited by 86
“For example, it has recently been demonstrated that a functional SNP in the l-opioid receptor gene predicts naltrexone efficacy as measured by relapse behavior (Oslin et al. 2003; for a first meta-analysis, see Chamorro et al. 2011).”
BackgroundRay, L. A., Barr, C. S., Blendy, J. A., Oslin, D., Goldman, D., & Anton, R. F. (2012) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01633.x · Cited by 79
Self-citationGenetics of alcohol dependence
Kimura, M., & Higuchi, S. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02190.x · Cited by 94
The Pharmacogenetics of Alcohol Use Disorder
Jones, J. D., Comer, S. D., & Kranzler, H. R. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12643 · Cited by 78
“Oslin et al. (2003) first reported that the Asp40 allele of Asn40Asp, encoded by an A118G SNP, predicted a significantly lower rate of relapse to heavy drinking in Alcohol Clin Exp Res.”
BackgroundSelf-citationTreatment of Late-Life Depression Complicated by Alcohol Dependence
Oslin, D. W. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200506000-00008 · Cited by 80
Self-citationPharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy
Sadee, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer, R. A., & Johnson, A. D. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.314 · Cited by 77
Individualised treatment in alcohol-dependent patients
Mann, K. F., & Hermann, D. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0153-7 · Cited by 79
Nikoshkov, A., Drakenberg, K., Wang, X., Horvath, M. C., Keller, E., & Hurd, Y. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710902105 · Cited by 79
Genetic Influences on Addiction: An Intermediate Phenotype Approach
(2013) · The MIT Press eBooks · doi:10.7551/mitpress/9391.001.0001 · Cited by 85
Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review
Lobmaier, P. P., Kunøe, N., Gossop, M., & Waal, H. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00194.x · Cited by 77
Grant, J. E., Odlaug, B. L., Schreiber, L. R. N., & Kim, S. W. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000037 · Cited by 74
Setiawan, E., Pihl, R. O., Cox, S. M. L., Gianoulakis, C., Palmour, R. M., Benkelfat, C., & Leyton, M. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01446.x · Cited by 77
“Preliminary evidence suggests that some of this variability is attributable to genetic variation of the OPRM1 gene (Anton et al., 2008; Oslin et al., 2003).”
BackgroundResultRay, L. A., Bujarski, S., MacKillop, J., Courtney, K. E., Monti, P. M., & Miotto, K. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01916.x · Cited by 75
“Some clinical studies have shown that G-allele carriers may respond better to naltrexone (Anton et al., 2008; Oslin et al., 2003), while other studies have failed to replicate these findings (Gelernter et al., 2007).”
Personalized Treatment of Alcohol Dependence
Kranzler, H. R., & McKay, J. R. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0296-5 · Cited by 73
Self-citationTargeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders
Niciu, M. J., & Arias, A. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0096-4 · Cited by 67
Srinivasan, S., Simms, J. A., Nielsen, C. K., Lieske, S. P., Bito-Onon, J. J., Yi, H., Hopf, F. W., Bonci, A., & Bartlett, S. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044726 · Cited by 73
Witkiewitz, K. A., Roos, C. R., Mann, K. F., & Kranzler, H. R. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14183 · Cited by 77
“DOI: 10.1111/acer.14183 Alcohol Clin Exp Res,Vol 43, No 11, 2019: pp 2395–2405 2395 ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH Vol. 43, No. 11 November 2019 some studies to respond better to naltrexone than Asn40 homozygotes (Chamorro et al., 2012; Oslin et al., 2003).”
BackgroundSelf-citationAssociation of Functional Opioid Receptor Genotypes With Alcohol Dependence in Koreans
Kim, S., Kim, C., Kang, D., Kim, Y., Byun, W., Kim, S., Park, J., Kim, M., & Oslin, D. W. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000130803.62768.ab · Cited by 74
Self-citationLitten, R. Z., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13093 · Cited by 69
Genomic medicine: genetic variation and its impact on the future of health care
Willard, H. F., Angrist, M. H., & Ginsburg, G. S. (2005) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1683 · Cited by 78
“In 2003, researchers showed that a single SNP in the m-opioid receptor gene had a measurable clinical impact on problem drinkers trying to stay sober (Oslin et al. 2003).”
BackgroundHeroin-assisted treatment in the Netherlands: History, findings, and international context
Blanken, P., van den Brink, W., Hendriks, V. M., Huijsman, I. A., Klous, M. G., Rook, E. J., Wakelin, J. S., Barendrecht, C., Beijnen, J. H., & van Ree, J. M. (2010) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(10)70001-8 · Cited by 86
“, 2006), or at the genetic level (Ooteman et al., 2009; Oslin et al., 2003) should be tested as outcome predictors.”
BackgroundPharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study
Ray, L. A., Bujarski, S., Chin, P. F., & Miotto, K. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.192 · Cited by 76
“…Asp40 allele of the OPRM1 gene found to predict a more positive response to naltrexone in the human laboratory (Ray and Hutchison, 2007a) and in clinical trials (Anton et al, 2008; Kim et al, 2009; Oslin et al, 2003) is markedly more prevalent among individuals of Asian descent (Arias et al, 2006).”
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias, A. J., Armeli, S., Gelernter, J. E., Covault, J., Kallio, A., Karhuvaara, S., Koivisto, T., Mäkelä, R., & Kranzler, H. R. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00735.x · Cited by 74
“Using data from Oslin et al. (2003), which compared the risk of relapse to heavy drinking within the group treated with naltrexone, we estimated the effect size to be .695 (Chinn, 2000), which is a medium effect size (Cohen, 1988).”
BackgroundMethodResultInfluentialSelf-citationLasek, A. W., Janak, P. H., He, L., Whistler, J. L., & Heberlein, U. (2007) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00303.x · Cited by 69
“In line with this suggestion, the response to naltrexone treatment is related to the presence of a particular polymorphism, A118G, in the OPRM1 gene that encodes the MOR (Oslin et al. 2003).”
BackgroundResting state connectivity best predicts alcohol use severity in moderate to heavy alcohol users
Fede, S. J., Grodin, E. N., Dean, S. F., Diazgranados, N., & Momenan, R. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101782 · Cited by 66
“A portion of that may be unexplainable, but demographic features, individual differences, genetics, and family dynamics may contribute to prediction of alcohol use severity and outcomes (Behrendt et al., 2017; Oslin et al., 2003; Rosenström et al., 2017; Umut et al., 2017).”
BackgroundAcamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
Witkiewitz, K. A., Saville, & Hamreus (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s23184 · Cited by 78
Bujarski, S., MacKillop, J. M., & Ray, L. A. (2012) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0027379 · Cited by 71
“Pharmacogenetic studies of naltrexone have found that the G allele carriers exhibit greater naltrexone-induced blunting of alcohol high (Ray & Hutchison, 2007), and lower relapse rates in clinical trials of naltrexone for alcoholism (Anton et al., 2008; Oslin et al., 2003).”
BackgroundResultA preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.
Ray, L. A., Miranda, R., MacKillop, J., McGeary, J., Tidey, J. W., Rohsenow, D. J., Gwaltney, C., Swift, R. W., & Monti, P. M. (2009) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0015700 · Cited by 69
“This SNP has been found to predict more favorable responses to naltrexone in the laboratory (Ray & Hutchison, 2007) and in clinical trials (Anton et al., 2008; Oslin et al., 2003).”
BackgroundRole of pharmacogenetics in variable response to drugs: focus on opioids
Kadiev, E., Patel, V., Rad, P., Thankachan, L., Tram, A., Weinlein, M., Woodfin, K., Raffa, R. B., & Nagar, S. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.1.77 · Cited by 77
Acamprosate in Alcohol Dependence: Implications of a Unique Mechanism of Action
Littleton, J. M. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318156c26f · Cited by 67
Finney, J. W., Humphreys, K. N., Kivlahan, D. R., & Harris, A. H. S. (2011) · American Journal of Public Health · doi:10.2105/ajph.test.2011.300153 · Cited by 69
REVIEW: Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone
Oslin, D. W., Berrettini, W. H., & O’Brien, C. P. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00036.x · Cited by 71
Self-citationFuture pharmacological treatments for substance use disorders
Forray, A., & Sofuoglu, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04474.x · Cited by 74
Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence
Zhang, H., Herman, A. I., Kranzler, H. R., Anton, R. F., Simen, A. A., & Gelernter, J. (2012) · Journal of Human Genetics · doi:10.1038/jhg.2012.98 · Cited by 65
Self-citationInitial Evidence of an Association Between OPRM1 and Adolescent Alcohol Misuse
Miranda, R., Ray, L., Justus, A., Meyerson, L. A., Knopik, V. S., McGeary, J., & Monti, P. M. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.01073.x · Cited by 64
“Moreover, clinical trials indicate that G allele carriers benefit more from naltrexone treatment than those without the allele (e.g., Anton et al., 2008; Oroszi et al., 2009; Oslin et al., 2003), although this finding is not consistent across studies (Gelernter et al., 2007).”
MethodResultHermann, D., Hirth, N., Reimold, M., Batra, A., Smolka, M. N., Hoffmann, S., Kiefer, F., Noori, H. R., Sommer, W. H., Reischl, G., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.145 · Cited by 64
“Correspondingly, in the treatment of relapse, G-allele carriers of OPRM1 respond better to naltrexone, resulting in reduced heavy drinking days and an increase in abstinent days (Oslin et al., 2003; Anton et al., 2008; Chamorro et al., 2012).”
BackgroundWong, C. C. Y., & Schumann, G. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0104 · Cited by 68
“This same polymorphism in exon 1 of OPRM1 has been demonstrated to predict the clinical response to naltrexone in alcohol-dependent individuals (Oslin et al. 2003).”
BackgroundSubstance Use Disorders: Realizing the Promise of Pharmacogenomics and Personalized Medicine
Hutchison, K. E. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.121208.131441 · Cited by 64
Oslin, D. W., Lynch, K. G., Pettinati, H. M., Kampman, K. M., Gariti, P., Gelfand, L., Ten Have, T., Wortman, S., Dundon, W., Dackis, C., et al. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00698.x · Cited by 64
“In addition, recent lines of investigation suggest that a genetic polymorphism may be associated with treatment response (Oslin et al., 2003).”
BackgroundSelf-citationPharmacogenetics of Alcohol and Alcohol Dependence Treatment
Kranzler, H. R., & Edenberg, H. J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791516387 · Cited by 66
Self-citationPharmacogenetics of alcohol, nicotine and drug addiction treatments: Pharmacogenetics of addiction
Sturgess, J. E., George, T. P., Kennedy, J. L., Heinz, A., & Müller, D. J. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00287.x · Cited by 62
“Three randomized, placebo-controlled studies (Oslin et al. 2003; Ray & Hutchison 2007; Anton et al. 2008; Kim et al. 2009) have shown that individuals with a G allele display longer abstinence and a greater reduction in the positive effects of alcohol when taking NTX.”
BackgroundInfluentialPharmacogenomics of the Human µ-Opioid Receptor
Kasai, S., & Ikeda, K. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.68 · Cited by 67
Comer, S. D., Bickel, W. K., Yi, R., de Wit, H., Higgins, S. T., Wenger, G. R., Johanson, C., & Kreek, M. J. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833bb9f8 · Cited by 60
Anton, R. F., Voronin, K. E., Randall, P. K., Myrick, H., & Tiffany, A. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01807.x · Cited by 61
“This finding parallels data in human clinical laboratory studies (Ray et al., 2012) and clinical trials (Anton et al., 2008; Oslin et al., 2003) where naltrexone appears to exert a stronger effect on those individuals with the asp40 OPRM1 SNP.”
Bilbao, A., Robinson, J. E., Heilig, M. A., Malanga, C. J., Spanagel, R., Sommer, W. H., & Thorsell, A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.08.021 · Cited by 63
Zhou, Y., Proudnikov, D., Yuferov, V., & Kreek, M. J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.015 · Cited by 58
“…found that alcoholics seek a modest activation of the HPA axis, which may be effected by alcohol or a specific opioid antagonist such as naltrexone (Oslin et al., 2003; O’Malley et al., 2004; Kreek et al., 2004; Anton et al., 2008) It has been found that non-human primates have a natural variant…”
Barr, C. S., Chen, S. A., Schwandt, M. L., Lindell, S. G., Sun, H., Suomi, S. J., & Heilig, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.026 · Cited by 59
Glatt, S. J., Bousman, C., Wang, R. S., Murthy, K. K., Rana, B. K., Lasky-Su, J. A., Zhu, S. C., Zhang, R., Li, J., Zhang, B., et al. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.02.022 · Cited by 61
“…et al., 2004) has been negative, several studies have found effects of this SNP on therapeutic responses to naloxone among alcohol-dependent (Oslin et al., 2003) and opioid-dependent subjects (Hernandez-Avila et al., 2003), as well as the efficacy of nicotine replacement therapy among…”
BackgroundAshenhurst, J. R., Bujarski, S., & Ray, L. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.019 · Cited by 59
“Pharmacogenetic studies of the A118G SNP have found that G-allele carriers exhibit greater naltrexone-induced blunting of alcohol high (Ray and Hutchison, 2007) and lower relapse rates in clinical trials of naltrexone for alcoholism (Anton et al., 2008; Oslin et al., 2003).”
BackgroundCommon and specific liability to addiction: Approaches to association studies of opioid addiction
Nielsen, D. A., & Kreek, M. J. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.03.026 · Cited by 59
“In a study in central Sweden, the 118G variant was associated with alcoholism (Bart et al., 2005) and, in two studies, with the pharmacotherapeutic response to naltrexone treatment for alcoholism (Anton et al., 2008; Oslin et al., 2003).”
Alcohol research: past, present, and future
Gunzerath, L., Hewitt, B. G., Li, T., & Warren, K. R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05832.x · Cited by 59
Pathological Gambling: Neuropsychopharmacology and Treatment
Bullock, S. A., & Potenza, M. N. (2012) · Current Psychopharmacologye · doi:10.2174/2211556011201010067 · Cited by 76
Kovanen, L., Basnet, S., Castrén, S., Pankakoski, M., Saarikoski, S. T., Partonen, T., Alho, H., & Lahti, T. (2016) · European Addiction Research · doi:10.1159/000435876 · Cited by 53
Practitioner Review: Adolescent alcohol use disorders: assessment and treatment issues
Perepletchikova, F., Krystal, J. H., & Kaufman, J. (2008) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.01934.x · Cited by 63
The Biological Bases of Nicotine and Alcohol Co-Addiction
Li, T., Volkow, N. D., Baler, R., & Egli, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.004 · Cited by 55
The current clinical knowledge on the treatment of gambling disorder: A summary
Hloch, K., Mladěnka, P., Doseděl, M., Adriani, W., & Zoratto, F. (2017) · Synapse · doi:10.1002/syn.21976 · Cited by 56
“Specifically, allelic variants of the gene encoding l-opioid receptor have been linked to naltrexone treatment outcome in alcoholism (Gelernter et al., 2007; Oslin et al., 2003).”
BackgroundClinical neuropsychiatric considerations regarding nonsubstance or behavioral addictions
Potenza, M. N. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/mpotenza · Cited by 53
Ehlers, C. L., Lind, P. A., & Wilhelmsen, K. C. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-35 · Cited by 52
“In a study that combined data from three different clinical trials, Oslin and colleagues [32] demonstrated that carriers of the 118G allele had a significantly lower rate of relapse and a longer time to a return to heavy drinking when compared to those individuals who were homozygous for the 118A allele.”
Padula, A. E., Griffin, W. C., Lopez, M. F., Nimitvilai, S., Cannady, R., McGuier, N. S., Chesler, E. J., Miles, M. F., Williams, R. W., Randall, P. K., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.42 · Cited by 54
“Indeed, matching SNPs in the OPRM1 gene to naltrexone treatment leads to more successful clinical outcomes in individuals with AUDs (Anton et al, 2008; Anton et al, 2012; Oslin et al, 2003; Ray and Hutchison, 2007; Schacht et al, 2013).”
BackgroundSweet Liking Phenotype, Alcohol Craving and Response to Naltrexone Treatment in Alcohol Dependence
Garbutt, J. C., Osborne, M., Gallop, R., Barkenbus, J., Grace, K., Cody, M., Flannery, B., & Kampov-Polevoy, A. B. (2009) · Alcohol and Alcoholism · doi:10.1093/alcalc/agn122 · Cited by 54
“…problems (Monterosso et al., 2001; Rubio et al., 2005; Rohsenow et al., 2007; Tidey et al., 2008); early onset of alcohol problems (Rubio et al., 2005) and the A118G variant polymorphism in the µ-opioid receptor (Oslin et al., 2003; Anton et al., 2008; not confirmed by Gelernter et al., 2007).”
BackgroundDepot naltrexone decreases rewarding properties of sugar in patients with opioid dependence
Langleben, D. D., Busch, E. L., O’Brien, C. P., & Elman, I. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2503-1 · Cited by 54
“2011) including allelic variations in specific opioid genes, for example OPRM1 (Oslin et al. 2003), STT performance predicted naltrexone effects on the brain responses to alcohol”
Self-citationJob, M. O., Tang, A., Hall, F. S., Sora, I., Uhl, G. R., Bergeson, S. E., & Gonzales, R. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.016 · Cited by 56
“Oslin et al. (2003) recently reported that a functional polymorphism of the human gene that codes for the MOPr is associated with the clinical response to naltrexone in treating alcohol dependence.”
BackgroundWang, Y.-J., Huang, P., Ung, A., Blendy, J. A., & Liu‐Chen, L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.033 · Cited by 51
“In addition, individuals with the G118 allele had better treatment outcomes for nicotine and alcohol abuse (Oslin et al., 2003; Lerman et al., 2004; Ray and Hutchison, 2007).”
BackgroundPratt, W. M., & Davidson, D. (2009) · Alcohol and Alcoholism · doi:10.1093/alcalc/agp007 · Cited by 51
“…two treatment studies indicate that alcoholic subjects with at least one copy of the variant allele who were treated with naltrexone experienced improved clinical outcomes compared to those treated with placebo and those who did not carry the variant allele (Oslin et al., 2003; C© The Author 2009.”
Medications for treating alcohol use disorder: A narrative review
Kranzler, H. R., & Hartwell, E. E. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15118 · Cited by 59
Self-citationHendershot, C. S., Claus, E. D., & Ramchandani, V. A. (2014) · Addiction Biology · doi:10.1111/adb.12165 · Cited by 54
“…convergence, including associations with alcohol-induced striatal dopamine release (Heilig et al. 2011; Ramchandani et al. 2011) and differential reduction of alcohol consumption during treatment with the μ-opioid receptor antagonist naltrexone (Oslin et al. 2003; Vallender et al. 2010).”
BackgroundBarnes, J. C., & Boutwell, B. B. (2012) · Journal of Criminal Justice · doi:10.1016/j.jcrimjus.2011.12.003 · Cited by 56
“A polymorphism in the gene that encodes for the μ-opioid receptor (OPRM1), for example, has been linked to success in treatment for alcoholism (Oslin et al., 2003).”
BackgroundPharmacotherapy for Alcohol Dependence: Anticraving Medications for Relapse Prevention
Jung, Y., & Namkoong, K. (2006) · Yonsei Medical Journal · doi:10.3349/ymj.2006.47.2.167 · Cited by 57
A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys☆
Vallender, E. J., Rüedi‐Bettschen, D., Miller, G. M., & Platt, D. M. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.01.005 · Cited by 49
“Naltrexone more effectively blunted the reported alcohol-induced high in individuals with the G118 allele (Ray and Hutchison, 2007) and alcoholics with the G118 allele showed significantly lower rates of relapse and a longer time to return to heavy drinking (Oslin et al., 2003).”
Background
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.